Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLUL | P15104 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | GCLC | P48506 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1980143 | 1.00 | GLUL (0.52) | GLULFOLH1PTGS1SLC7A11GCLC | |
| SCHEMBL195643 | 1.00 | GLUL (0.52) | GLULFOLH1PTGS1SLC7A11GCLC | |
| SCHEMBL28229605 | 0.97 | GLUL (0.50) | GLULFOLH1PTGS1SLC7A11GCLC | |
| SCHEMBL23649439 | 0.97 | GLUL (0.50) | GLULFOLH1PTGS1SLC7A11GCLC | |
| Norvaline SCHEMBL6924739 | 0.85 | GCLC (0.53) | GLULGCLC | |
| SCHEMBL13892954 | 0.80 | PTGS1 (0.48) | GLULPTGS1SLC7A11GCLC | |
| SCHEMBL19697646 | 0.80 | PTGS1 (0.48) | GLULPTGS1SLC7A11GCLC | |
| SCHEMBL5054657 | 0.80 | PTGS1 (0.48) | GLULPTGS1SLC7A11GCLC | |
| SCHEMBL28341260 | 0.79 | GABBR2 (0.42) | GLULFOLH1 | |
| SCHEMBL13997104 | 0.77 | PTGS1 (0.44) | GLULPTGS1SLC7A11GCLC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583872-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2025-07-16 | — | — | EP | claimed |
| WO-2024088712-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2024-05-02 | — | — | WO | claimed |
| EP-3966344-A1 | KINASE SCREENING ASSAYS | University of Newcastle Upon Tyne (GB) | 2022-03-16 | — | — | EP | claimed |
| CN-105524492-A | Simple low-cost magnetic fine particle surface active group introduction method | UNIV SICHUAN | 2016-04-27 | — | — | CN | claimed |
| CN-102176818-A | Antimicrobial gel formulations | NOVABAY PHARMACEUTICALS INC | 2011-09-07 | — | — | CN | claimed |
| EP-4583872-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024088712-A1 | MGLUR5 RECEPTOR ANTAGONISTS FOR USE IN PREVENTION AND/OR TREATMENT OF BONE MARROW LESIONS (BML) AND/OR OSTEOPOROSIS, CARTILAGE LOSS, OSTEOSCLEROSIS, OSTEITIS IN A MAMMAL | ORPHELION AB (SE) | 2024-05-02 | — | — | WO | disclosed |
| EP-4284343-A1 | PARTICLES COMPRISING AMORPHOUS DIVALENT METAL CARBONATE | Amorphical Ltd. (IL) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023164661-A1 | ALTERATION OF NUTRIENT PREFERENCES VIA MODULATION OF NUTRIENT RECEPTORS IN THE GUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-31 | — | — | WO | disclosed |
| EP-4117685-A1 | AMORPHOUS CALCIUM CARBONATE FOR TREATMENT OF ACIDOSIS | Amorphical Ltd. (IL) | 2023-01-18 | — | — | EP | disclosed |
| WO-2022162667-A1 | PARTICLES COMPRISING AMORPHOUS DIVALENT METAL CARBONATE | AMORPHICAL LTD. (IL) | 2022-08-04 | — | — | WO | disclosed |
| US-11326169-B2 | Method of producing an aptamer and uses thereof | CITY UNIVERSITY OF HONG KONG (HK) | 2022-05-10 | — | — | US | disclosed |
| CN-109996453-A | Compounds for modulating calcium sensitive receptor activity for modulating kokumi taste and pet foods containing same | 马斯公司 | 2019-07-09 | — | — | CN | disclosed |
| EP-2632470-B1 | PERSONAL CARE COMPOSITIONS COMPRISING A PYRITHIONE AND AN IRON CHELATOR | PROCTER & GAMBLE (US) | 2018-02-28 | — | — | EP | disclosed |
| CN-105524492-A | Simple low-cost magnetic fine particle surface active group introduction method | UNIV SICHUAN | 2016-04-27 | — | — | CN | disclosed |
| CN-102176818-A | Antimicrobial gel formulations | NOVABAY PHARMACEUTICALS INC | 2011-09-07 | — | — | CN | disclosed |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| CN-1144529-A | Heterocyclic compounds, their preparation and use | NOVO NORDISK AS (DK) | 1997-03-05 | — | — | CN | disclosed |
| US-5523430-A | Protein farnesyl transferase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | GLUL 1420/4885FOLH1 1947/4885PTGS1 620/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | GLUL 1997/4885FOLH1 132/4885PTGS1 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.